Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen, targeting a first IND within 18 months.
Lyora Therapeutics will try to revive several early-stage genetic eye disease programs previously held by Editas Medicine and Biogen.
The biotech was co-founded by Luk …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go…
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a…
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
Addition Therapeutics is working on a genetic medicine that would turn a patient’s liver cells into little factories to…
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
